What is the latest SAKAR stock price?
The latest stored price for SAKAR is Rs 1,179.80 as of 2026-09-18.
gimli
SAKAR stock AI analysis
SAKAR Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
SAKAR HEALTHCARE LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available SAKAR price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,179.80
1W return
+5.59%
1M return
+32.01%
3M return
+48.23%
6M return
+118.74%
1Y return
+245.07%
Market cap
₹2,589.65 cr
PE
71.76
PB
7.98
ROE
+11.83%
ROCE
+10.67%
RSI
69.82
Turnover
₹17.40 cr
Why it can matter in screens
- Momentum: SAKAR is above 50DMA, above 200DMA; RSI is 69.82.
- Returns: 1D +4.45%, 1W +5.59%, 1M +32.01%, 3M +48.23%, 1Y +245.07%.
- Trend levels: 52W high ₹1,211.00, 52W low ₹755.00, off high -2.58%.
- Liquidity: latest turnover is ₹17.40 cr; volume vs 20D is +0.70%.
- Valuation/profitability: PE 71.76, PB 7.98, ROE +11.83%, ROCE +10.67%.
- Growth: 3Y sales CAGR +23.58%, 3Y profit CAGR +33.67%.
Quick Answers
Is SAKAR above its 50DMA and 200DMA?
SAKAR is above 50DMA, above 200DMA. The latest 50DMA is 939.04 and the latest 200DMA is 658.50.
What are SAKAR PE, ROE and ROCE?
SAKAR has PE 71.76, ROE +11.83%, and ROCE +10.67% in Gimli's latest available snapshot.
How has SAKAR performed recently?
SAKAR has returned +32.01% over 1 month, +48.23% over 3 months, and +245.07% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 74.51 cr | 22.79 cr | 10.28 cr | 4.62 |
| 2026-03-31 | 71.10 cr | 26.41 cr | 11.02 cr | 4.96 |
| 2025-12-31 | 70.34 cr | 19.10 cr | 10.25 cr | 4.59 |
| 2025-09-30 | 57.56 cr | 12.57 cr | 4.54 cr | 2.03 |
| 2025-06-30 | 52.74 cr | 13.10 cr | 4.67 cr | 2.11 |
| 2025-03-31 | 50.24 cr | 15.91 cr | 5.76 cr | 2.66 |
| 2024-12-31 | 43.42 cr | 12.00 cr | n/a | nan |
| 2024-09-30 | 42.78 cr | 11.87 cr | n/a | 2.17 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 251.74 cr | 71.18 cr | 30.48 cr | nan |
| 2025-03-31 | 177.58 cr | 50.94 cr | 17.50 cr | 7.97 |
| 2024-03-31 | 153.35 cr | 40.70 cr | 11.67 cr | 5.69 |
| 2023-03-31 | 133.36 cr | 37.35 cr | 12.76 cr | 6.86 |
| 2022-03-31 | 130.40 cr | 31.26 cr | 15.24 cr | 10.09 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 481.01 cr | 0.04 cr | 55.30 cr | 324.45 cr |
| 2025-03-31 | 415.26 cr | 0.10 cr | 86.37 cr | 285.48 cr |
| 2024-03-31 | 388.66 cr | 0.26 cr | 79.35 cr | 262.33 cr |
| 2023-03-31 | 336.34 cr | 0.09 cr | 119.18 cr | 173.35 cr |
| 2022-03-31 | 267.76 cr | 0.03 cr | 92.86 cr | 127.45 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 49.26 cr | 20.91 cr | n/a |
| 2025-03-31 | 34.03 cr | 1.75 cr | n/a |
| 2024-03-31 | 24.47 cr | -35.09 cr | n/a |
| 2023-03-31 | 33.34 cr | -48.85 cr | n/a |
| 2022-03-31 | 24.64 cr | -10.91 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +52.52% | +12.13% | +11.37% | +0.00% | +23.98% | +0.00% |
| 2026-03-31 | +52.86% | +12.94% | +11.32% | +0.00% | +22.87% | +0.00% |
| 2025-12-31 | +52.86% | +13.05% | +11.36% | +0.00% | +22.73% | +0.00% |
| 2025-09-30 | +52.86% | +13.31% | +11.43% | +0.00% | +22.41% | +0.00% |
| 2025-06-30 | +52.86% | +13.41% | +11.25% | +0.00% | +22.48% | +0.00% |
| 2025-03-31 | +53.58% | +13.61% | +10.97% | +0.00% | +21.85% | +0.00% |
| 2024-12-31 | +53.58% | +13.58% | +10.88% | +0.00% | +21.96% | +0.00% |
| 2024-09-30 | +53.15% | +13.42% | +10.62% | +0.00% | +22.80% | +0.00% |
| 2024-06-30 | +53.15% | +13.52% | +10.62% | +0.00% | +22.71% | +0.00% |
| 2024-03-31 | +53.15% | +13.52% | +10.62% | +0.00% | +22.71% | +0.00% |
| 2023-12-31 | +53.15% | +13.76% | +10.62% | +0.00% | +22.47% | +0.00% |
| 2023-09-30 | +54.15% | +14.03% | +10.82% | +0.00% | +21.00% | +0.00% |
| 2023-09-01 | +54.15% | +14.03% | +10.82% | +0.00% | +21.00% | +0.00% |
| 2023-06-30 | +60.72% | +15.74% | +0.00% | +0.00% | +23.54% | +0.00% |
| 2023-03-31 | +60.72% | +15.74% | +0.00% | +0.00% | +23.54% | +0.00% |
| 2023-02-24 | +60.72% | +15.74% | +0.13% | +0.00% | +23.41% | +0.00% |
| 2022-12-31 | +62.10% | +16.12% | +0.33% | +0.00% | +21.45% | +0.00% |
| 2022-09-30 | +62.10% | +16.12% | +0.55% | +0.00% | +21.24% | n/a |
| 2022-07-08 | +62.10% | +0.00% | +16.11% | n/a | n/a | +0.00% |
| 2022-06-30 | +67.54% | +0.00% | +8.76% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze SAKAR HEALTHCARE with valuation, momentum and industry peers
- Compare SAKAR with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare SAKAR with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.